The US District Court for the District of Delaware has upheld the validity of a GSK-held patent that covers two HIV drugs marketed in the US by ViiV Healthcare.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at achoudhury@worldipreview.com
ViiV Healthcare, GSK, Teva, pharmaceuticals, patent validity
